120
Participants
Start Date
January 31, 2019
Primary Completion Date
July 3, 2019
Study Completion Date
July 3, 2019
XC221
Participants will receive 200 mg XC221 once a day during 3 days
Placebo
Participants will receive Placebo once a day during 3 days
"Non-governmental Healthcare Institution N.A.Semashko Road Clinical Hospital at the Lyublino station of the open joint-stock company Russian Railways", Moscow
"State budget institution of health care of the Moscow region Krasnogorsk city hospital number 1", Krasnogorsk
"Federal State Budgetary Educational Institution of Higher Education Yaroslavl State Medical University of the Ministry of Health of the Russian Federation", Yaroslavl
State Budgetary Healthcare Institution (SBHI) of Yaroslavl region, Yaroslavl
"Federal State Budgetary Institution of Health Northern Medical Clinical Center named after NA Semashko of the Federal Medical and Biological Agency", Arkhangelsk
The Center for Prevention and Fight about AIDS and Infectious Diseases, Saint Petersburg
"LLC Aurora Medi", Saint Petersburg
The Consulting and Diagnostic Center with out-patient help of the Administration of the President of the Russian Federation, Saint Petersburg
Research Institute of Influenza, Saint Petersburg
City Clinical Hospital №40 of Kurortny District, Saint Petersburg
"LLC Astarta", Saint Petersburg
"Regional State Budgetary Institution of Health Belgorod Regional Clinical Hospital of St. Joasaph", Belgorod
Kuban State Medical University, Krasnodar
"Federal State Budgetary Educational Institution of Higher Education Ryazan State Medical University named after Academician I.P. Pavlova of the Ministry of Health of the Russian Federation", Ryazan
Ryazan State Medical University n.a. Pavlov, Ryazan
City Clinical Hospital №9, Izhevsk
RSV Therapeutics LLC
INDUSTRY
PHARMENTERPRISES LLC
INDUSTRY